President Biden Signs New Legislation to Identify and Mitigate Organizational Conflicts of Interest in Federal Acquisition
Client Alert | 1 min read | 01.03.23
On December 27, 2022, President Biden signed into law the Preventing Organizational Conflicts of Interest in Federal Acquisition Act (S.3905) to strengthen the current rules relating to identification and mitigation of organizational conflicts of interest (OCIs) in federal acquisition. The Act focuses on updating the current FAR provision, Subpart 9.5, to provide clear definitions, examples, and guidance on potential OCIs and to consider expanding the Subpart to cover certain commercial and foreign relationships.
As currently drafted, FAR Subpart 9.5 provides general rules governing OCIs. Case law at the Court of Federal Claims and the Government Accountability Office have further identified three types of OCIs, “biased ground rules,” “impaired objectivity,” and “unequal access to information.” Under the Act, the FAR Council is meant to provide specific definitions and examples of the three types of OCIs.
The Act also instructs the FAR Council to provide executive agencies with standard solicitation provisions and contract clauses to address OCIs. Executive agencies will be able to tailor the solicitation provisions and contract clauses as necessary to address concerns associated with conflicts of interest and any considerations unique to the executive agency.
The Act directs the FAR Council to update the FAR’s OCI provisions in the next 18 months. We are expecting the FAR Council to issue proposed regulations, and contractors should be prepared to review the proposed changes and modify practices if needed once the final rules are issued.
Contacts
Insights
Client Alert | 5 min read | 03.30.26
The EU Pharma Package: The Transferable Exclusivity Voucher Compromise Proposal
In our third alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission, the European Parliament , and the Council of the European Union on the transferable exclusivity voucher (TEV) for priority antimicrobials.
Client Alert | 2 min read | 03.27.26
CMS Releases PY 2020 RADV Audit Methods and Instructions: Key Takeaways for Health Plans
Client Alert | 4 min read | 03.25.26
NAIC Intensifies AI Regulatory Focus: What Health Insurance Payors Need to Know
Client Alert | 11 min read | 03.25.26
White House National AI Policy Framework Calls for Preempting State Laws, Protecting Children





